검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | DOAC (Direct Oral Anticoagulant, Direct Oral Anticoagulant (DOAC)) Janssen Research & Development, LL…·Carcinoma, Non-small-Cell Lung 76 trials |
|---|---|
Overview Program | Direct Oral Anticoagulant (DOAC) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-small-Cell Lung |
Overview Indication | Carcinoma, Non-small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of DOACs targeting thrombin or FXa on the metastasis of murine melanoma B16 cells implanted in mice |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran.. The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a… |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | DOAC (Direct Oral Anticoagulant, Direct Oral Anticoagulant (DOAC)) Janssen Research & Development, LL…·Carcinoma, Non-small-Cell Lung 76 trials |
|---|---|
Overview Program | Direct Oral Anticoagulant (DOAC) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-small-Cell Lung |
Overview Indication | Carcinoma, Non-small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of DOACs targeting thrombin or FXa on the metastasis of murine melanoma B16 cells implanted in mice |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran.. The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a… |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교